APO Research
Talk to an analyst

APO RESEARCH · REPORT

Fatty Liver Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Fatty Liver Drugs Market Outlook and Growth Opportunities 2026

30 December 2025193 pages

Choose your research edition.

Industry ResearchFatty Liver Drugs Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Fatty Liver Drugs Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Fatty Liver Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Fatty Liver Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Fatty Liver Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Fatty Liver Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Fatty Liver Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Fatty Liver Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Fatty Liver Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Fatty Liver Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Fatty Liver Drugs market include Allergan, Astra Zenca, Conatus, Gilead Sciences, Hepion Pharmaceuticals, Immuron, Intercept Pharmaceuticals, Madrigal and Merk, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Fatty Liver Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Fatty Liver Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Fatty Liver Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Fatty Liver Drugs market.

Fatty Liver Drugs Segment by Company

Allergan

Astra Zenca

Conatus

Gilead Sciences

Hepion Pharmaceuticals

Immuron

Intercept Pharmaceuticals

Madrigal

Merk

Pfizer

Novartis

Takeda

Fatty Liver Drugs Segment by Type

ALD

NAFLD

Fatty Liver Drugs Segment by Application

Hospital

Clinic

Others

Fatty Liver Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Fatty Liver Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Fatty Liver Drugs key companies, revenue, market share, and recent developments.

3. To split the Fatty Liver Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Fatty Liver Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Fatty Liver Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Fatty Liver Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fatty Liver Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Fatty Liver Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fatty Liver Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Fatty Liver Drugs industry.

Chapter 3: Detailed analysis of Fatty Liver Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Fatty Liver Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Fatty Liver Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Fatty Liver Drugs Industry Trends Table 2. Fatty Liver Drugs Industry Drivers Table 3. Fatty Liver Drugs Industry Opportunities and Challenges Table 4. Fatty Liver Drugs Industry Restraints Table 5. Global Fatty Liver Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Fatty Liver Drugs Revenue Share by Company (2021-2026) Table 7. Global Fatty Liver Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Fatty Liver Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Fatty Liver Drugs Company, Product Type & Application Table 10. Global Fatty Liver Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Fatty Liver Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of ALD Table 15. Significant Companies of NAFLD Table 16. Global Fatty Liver Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Fatty Liver Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Fatty Liver Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Fatty Liver Drugs Sales Value Share by Type (2021-2026) Table 20. Global Fatty Liver Drugs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Others Table 24. Global Fatty Liver Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Fatty Liver Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Fatty Liver Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Fatty Liver Drugs Sales Value Share by Application (2021-2026) Table 28. Global Fatty Liver Drugs Sales Value Share by Application (2027-2032) Table 29. Global Fatty Liver Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Fatty Liver Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Fatty Liver Drugs Sales Value Share by Region (2021-2026) Table 32. Global Fatty Liver Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Fatty Liver Drugs Sales Value Share by Region (2027-2032) Table 34. Global Fatty Liver Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Fatty Liver Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Fatty Liver Drugs Sales Value Market Share by Country (2021-2026) Table 37. Global Fatty Liver Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Fatty Liver Drugs Sales Value Market Share by Country (2027-2032) Table 39. Allergan Company Information Table 40. Allergan Business Overview Table 41. Allergan Fatty Liver Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Allergan Fatty Liver Drugs Product Portfolio Table 43. Allergan Recent Development Table 44. Astra Zenca Company Information Table 45. Astra Zenca Business Overview Table 46. Astra Zenca Fatty Liver Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Astra Zenca Fatty Liver Drugs Product Portfolio Table 48. Astra Zenca Recent Development Table 49. Conatus Company Information Table 50. Conatus Business Overview Table 51. Conatus Fatty Liver Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Conatus Fatty Liver Drugs Product Portfolio Table 53. Conatus Recent Development Table 54. Gilead Sciences Company Information Table 55. Gilead Sciences Business Overview Table 56. Gilead Sciences Fatty Liver Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Gilead Sciences Fatty Liver Drugs Product Portfolio Table 58. Gilead Sciences Recent Development Table 59. Hepion Pharmaceuticals Company Information Table 60. Hepion Pharmaceuticals Business Overview Table 61. Hepion Pharmaceuticals Fatty Liver Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Hepion Pharmaceuticals Fatty Liver Drugs Product Portfolio Table 63. Hepion Pharmaceuticals Recent Development Table 64. Immuron Company Information Table 65. Immuron Business Overview Table 66. Immuron Fatty Liver Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Immuron Fatty Liver Drugs Product Portfolio Table 68. Immuron Recent Development Table 69. Intercept Pharmaceuticals Company Information Table 70. Intercept Pharmaceuticals Business Overview Table 71. Intercept Pharmaceuticals Fatty Liver Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Intercept Pharmaceuticals Fatty Liver Drugs Product Portfolio Table 73. Intercept Pharmaceuticals Recent Development Table 74. Madrigal Company Information Table 75. Madrigal Business Overview Table 76. Madrigal Fatty Liver Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Madrigal Fatty Liver Drugs Product Portfolio Table 78. Madrigal Recent Development Table 79. Merk Company Information Table 80. Merk Business Overview Table 81. Merk Fatty Liver Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Merk Fatty Liver Drugs Product Portfolio Table 83. Merk Recent Development Table 84. Pfizer Company Information Table 85. Pfizer Business Overview Table 86. Pfizer Fatty Liver Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Pfizer Fatty Liver Drugs Product Portfolio Table 88. Pfizer Recent Development Table 89. Novartis Company Information Table 90. Novartis Business Overview Table 91. Novartis Fatty Liver Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Novartis Fatty Liver Drugs Product Portfolio Table 93. Novartis Recent Development Table 94. Takeda Company Information Table 95. Takeda Business Overview Table 96. Takeda Fatty Liver Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Takeda Fatty Liver Drugs Product Portfolio Table 98. Takeda Recent Development Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Fatty Liver Drugs Product Image Figure 2. Global Fatty Liver Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Fatty Liver Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Fatty Liver Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. ALD Image Figure 8. NAFLD Image Figure 9. Global Fatty Liver Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Fatty Liver Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Fatty Liver Drugs Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Others Image Figure 15. Global Fatty Liver Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Fatty Liver Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Fatty Liver Drugs Sales Value Share by Application (2021-2032) Figure 18. Global Fatty Liver Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Fatty Liver Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Fatty Liver Drugs Sales Value (2021-2032) & (US$ Million) Figure 21. North America Fatty Liver Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Fatty Liver Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Fatty Liver Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Fatty Liver Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Fatty Liver Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Fatty Liver Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. South America Fatty Liver Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Fatty Liver Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Fatty Liver Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Fatty Liver Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • ALD
  • NAFLD
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Allergan
  • Astra Zenca
  • Conatus
  • Gilead Sciences
  • Hepion Pharmaceuticals
  • Immuron
  • Intercept Pharmaceuticals
  • Madrigal
  • Merk
  • Pfizer
  • Novartis
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Fatty Liver Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Fatty Liver Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Fatty Liver Drugs Market Dynamics
  1. 2.1 Fatty Liver Drugs Industry Trends
  2. 2.2 Fatty Liver Drugs Industry Drivers
  3. 2.3 Fatty Liver Drugs Industry Opportunities and Challenges
  4. 2.4 Fatty Liver Drugs Industry Restraints
3 Fatty Liver Drugs Market by Company
  1. 3.1 Global Fatty Liver Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Fatty Liver Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Fatty Liver Drugs Company Ranking (2024-2026)
  4. 3.4 Global Fatty Liver Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Fatty Liver Drugs Company Product Type and Application
  6. 3.6 Global Fatty Liver Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Fatty Liver Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Fatty Liver Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Fatty Liver Drugs Market by Type
  1. 4.1 Fatty Liver Drugs Type Introduction
  2. 4.1.1 ALD
  3. 4.1.2 NAFLD
  4. 4.2 Global Fatty Liver Drugs Sales Value by Type
  5. 4.2.1 Global Fatty Liver Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Fatty Liver Drugs Sales Value by Type (2021-2032)
  7. 4.2.3 Global Fatty Liver Drugs Sales Value Share by Type (2021-2032)
5 Fatty Liver Drugs Market by Application
  1. 5.1 Fatty Liver Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Fatty Liver Drugs Sales Value by Application
  6. 5.2.1 Global Fatty Liver Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Fatty Liver Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Fatty Liver Drugs Sales Value Share by Application (2021-2032)
6 Fatty Liver Drugs Regional Value Analysis
  1. 6.1 Global Fatty Liver Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Fatty Liver Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Fatty Liver Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Fatty Liver Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Fatty Liver Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Fatty Liver Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Fatty Liver Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Fatty Liver Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Fatty Liver Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Fatty Liver Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Fatty Liver Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Fatty Liver Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Fatty Liver Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Fatty Liver Drugs Sales Value Share by Country, 2025 VS 2032
7 Fatty Liver Drugs Country-level Value Analysis
  1. 7.1 Global Fatty Liver Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Fatty Liver Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Fatty Liver Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Fatty Liver Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Fatty Liver Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Fatty Liver Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Fatty Liver Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan
  2. 8.1.1 Allergan Company Information
  3. 8.1.2 Allergan Business Overview
  4. 8.1.3 Allergan Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Fatty Liver Drugs Product Portfolio
  6. 8.1.5 Allergan Recent Developments
  7. 8.2 Astra Zenca
  8. 8.2.1 Astra Zenca Company Information
  9. 8.2.2 Astra Zenca Business Overview
  10. 8.2.3 Astra Zenca Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Astra Zenca Fatty Liver Drugs Product Portfolio
  12. 8.2.5 Astra Zenca Recent Developments
  13. 8.3 Conatus
  14. 8.3.1 Conatus Company Information
  15. 8.3.2 Conatus Business Overview
  16. 8.3.3 Conatus Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Conatus Fatty Liver Drugs Product Portfolio
  18. 8.3.5 Conatus Recent Developments
  19. 8.4 Gilead Sciences
  20. 8.4.1 Gilead Sciences Company Information
  21. 8.4.2 Gilead Sciences Business Overview
  22. 8.4.3 Gilead Sciences Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Gilead Sciences Fatty Liver Drugs Product Portfolio
  24. 8.4.5 Gilead Sciences Recent Developments
  25. 8.5 Hepion Pharmaceuticals
  26. 8.5.1 Hepion Pharmaceuticals Company Information
  27. 8.5.2 Hepion Pharmaceuticals Business Overview
  28. 8.5.3 Hepion Pharmaceuticals Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hepion Pharmaceuticals Fatty Liver Drugs Product Portfolio
  30. 8.5.5 Hepion Pharmaceuticals Recent Developments
  31. 8.6 Immuron
  32. 8.6.1 Immuron Company Information
  33. 8.6.2 Immuron Business Overview
  34. 8.6.3 Immuron Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Immuron Fatty Liver Drugs Product Portfolio
  36. 8.6.5 Immuron Recent Developments
  37. 8.7 Intercept Pharmaceuticals
  38. 8.7.1 Intercept Pharmaceuticals Company Information
  39. 8.7.2 Intercept Pharmaceuticals Business Overview
  40. 8.7.3 Intercept Pharmaceuticals Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Intercept Pharmaceuticals Fatty Liver Drugs Product Portfolio
  42. 8.7.5 Intercept Pharmaceuticals Recent Developments
  43. 8.8 Madrigal
  44. 8.8.1 Madrigal Company Information
  45. 8.8.2 Madrigal Business Overview
  46. 8.8.3 Madrigal Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Madrigal Fatty Liver Drugs Product Portfolio
  48. 8.8.5 Madrigal Recent Developments
  49. 8.9 Merk
  50. 8.9.1 Merk Company Information
  51. 8.9.2 Merk Business Overview
  52. 8.9.3 Merk Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Merk Fatty Liver Drugs Product Portfolio
  54. 8.9.5 Merk Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer Fatty Liver Drugs Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Novartis
  62. 8.11.1 Novartis Company Information
  63. 8.11.2 Novartis Business Overview
  64. 8.11.3 Novartis Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novartis Fatty Liver Drugs Product Portfolio
  66. 8.11.5 Novartis Recent Developments
  67. 8.12 Takeda
  68. 8.12.1 Takeda Company Information
  69. 8.12.2 Takeda Business Overview
  70. 8.12.3 Takeda Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Takeda Fatty Liver Drugs Product Portfolio
  72. 8.12.5 Takeda Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst